Loading...

Pandion Therapeutics ($PAND)

Stock Image

PAND Overview

Pandion Therapeutics, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases.Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases.The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract.It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Pandion Therapeutics

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.